CJC-1295 / Ipamorelin Blend
This blend combines CJC-1295 (a GHRH analogue) with Ipamorelin (a selective ghrelin receptor agonist) into a single subcutaneous injection. GHRH and ghrelin act on parallel pathways at the pituitary, and the combination produces a GH pulse roughly twice the amplitude of either compound alone.1
CJC-1295 / Ipamorelin Blend at a glance
This blend combines CJC-1295 (a GHRH analogue) with Ipamorelin (a selective ghrelin receptor agonist) into a single subcutaneous injection. GHRH and ghrelin act on parallel pathways at the pituitary, and the combination produces a GH pulse roughly twice the amplitude of either compound alone.1
Ipamorelin is selected over older GHRPs (GHRP-2, GHRP-6) because of its clean profile: minimal effect on cortisol or prolactin and no meaningful appetite spike.2 This is the most-prescribed GH peptide pairing at Luxbae and the foundation of most adult-onset GH-restoration protocols.
CJC-1295 binds GHRH receptors; Ipamorelin binds GHS-R1a (ghrelin) — together they produce a stronger pulse than either alone.1
Cleanest pharmacology, predictable IGF-1 response, single nightly injection — the workhorse of adult GH-axis support.
What the research actually shows
CJC-1295 / Ipamorelin Blend has been studied across multiple modalities. The summaries below cite peer-reviewed sources; individual response varies and is not guaranteed.
Combined effect at pituitary substantially exceeds either compound alone.1
Predictable rise in serum IGF-1 toward age-appropriate upper-normal.
Lean-mass shifts and reduced adiposity in middle-aged adults on sustained protocols.3
Ipamorelin selectivity avoids cortisol and prolactin elevation seen with older GHRPs.2
GHRH-driven slow-wave sleep increase consistently reported.
One nightly stick versus two — adherence advantage on long protocols.
Your consultation is complimentary. Our medical team reviews your goals, current treatments, and history before recommending anything.
How a CJC-1295 / Ipamorelin Blend protocol typically runs at Luxbae
Dosing, cadence, and delivery method are tailored to you. The outline below describes the most common variant; your provider personalizes based on labs, current treatments, and goals.
Baseline IGF-1, fasting glucose, A1C, and history reviewed.
Nightly subcutaneous injection pre-sleep at protocol-standard dose.
IGF-1 rechecked at 6–8 weeks; dose adjusted to keep within age range.
Cyclical breaks every 12–16 weeks to preserve receptor sensitivity.
Frequently sequenced alongside
- Standalone CJC-1295 for protocol flexibility.
- Standalone Ipamorelin alone.
- Tesa / Ipa / MOTS-c Blend for advanced protocols.
- IGF-1 LR3 for direct IGF-1 support.
- Morpheus8 for collagen amplification.
Who it’s for — and who should avoid it
CJC-1295 / Ipamorelin Blend eligibility is confirmed during your medical consultation; your full medical history must be disclosed.
- Adults with declining GH axis.
- Body-composition goals.
- Sleep depth improvement.
- Recovery enhancement.
- No history of malignancy.
- Pregnancy or breastfeeding.
- Children and adolescents.
- Acute infection or autoimmune flare.
- Known peptide hypersensitivity.
- Active or recent malignancy.
- Untreated severe sleep apnea.
- Active proliferative retinopathy.
Possible side effects
Injection-site reactions, transient water retention, occasional headache, mild paresthesias at initiation.
FDA & regulatory note
Neither CJC-1295 nor Ipamorelin is FDA-approved. Prescribed as compounded protocol under medical supervision.
Dr. Ernst von Schwarz, MD, PhD
Professor Dr. Ernst von Schwarz — triple board-certified clinical and academic cardiologist, clinical professor of medicine at UCLA, and a three-decade pioneer in stem cell and regenerative medicine research — personally directs Luxbae’s peptide program. He has authored more than 150 peer-reviewed scientific papers and lectures internationally on cardiovascular and regenerative medicine. Every CJC-1295 / Ipamorelin Blend protocol at Luxbae is prescribed and monitored under his direction.
Meet Dr. von SchwarzCJC-1295 / Ipamorelin Blend FAQ
Why combine them?
How fast do results show?
Will I need to inject forever?
Side effects I’ll feel?
Can I take it in the morning?
Safe with TRT?
Clinical References
Reviewed by Dr. Ernst von Schwarz and the Luxbae medical team. Statements on this page are educational and supported by the following peer-reviewed sources. Individual results vary.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. View
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. View
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. View
- Sinha DK, Balasubramanian A, et al. Beyond the androgen receptor: peptides. Transl Androl Urol. 2020. View
Start your CJC-1295 / Ipamorelin Blend protocol at Luxbae West Hollywood
Your consultation is complimentary. We’ll walk you through how CJC-1295 / Ipamorelin Blend fits your goals, what labs (if any) we’d run, and how it would sequence with the rest of your aesthetic plan.